|Bid||2.270 x 8300|
|Ask||2.280 x 20400|
|Day's range||2.190 - 2.280|
|52-week range||2.000 - 27.976|
|PE ratio (TTM)||N/A|
|Earnings date||6 Nov 2017 - 10 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.22|
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Axovant Sciences (NASDAQ:AXON) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its January 8, 2018 press release. In the results of the pilot Phase 2 Visual Hallucination study, the post-hoc subset analysis of patients with a baseline Scale for the Assessment of Positive Symptoms - Parkinson's Disease (SAPS-PD) score of greater than 8.0 was misreported. The previously reported data for this population (n=19) that nelotanserin treatment at 40 mg for two weeks followed by 80 mg for two weeks resulted in a 1.21 point improvement (p=0.011, unadjusted) were incorrect.
Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...
Axovant Sciences lost half of its market value Monday after it said a drug once intended to treat Alzheimer’s disease didn’t meet certain goals in recent studies.
The company flunked a mid-stage study testing the treatment on patients with dementia with Lewy bodies, three months after stopping the development of the drug, intepirdine, for treating Alzheimer's. Treatments for neurological disorders, like Alzheimer's and Parkinson's, could rake in blockbuster sales for drug developers but these drugs are expensive to develop and high failure rates have discouraged companies from pursuing their development. Pfizer Inc (PFE.N) said on Sunday it was abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease.
Shares of Axovant Sciences Ltd. plunged 46% toward a record low in premarket trade Monday, after the biopharmaceutical company said it would discontinue its intepirdine program for the treatment of dementia ...
BASEL, Switzerland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th at 10:00 a.m. PST at the Westin St. Francis Hotel in San Francisco. In addition, he will participate in a break-out session immediately following the presentation.
Last week, Vivek Ramaswamy's biggest bet, on the Alzheimer's drug being developed by Axovant Sciences, failed. This morning, one of his smaller ones came through: a treatment for uterine fibroids being tested by Myovant, another company started by Ramaswamy's vehicle, Roivant.
Biotech stocks are on fire this year, and a key event this week could spark a massive move in one name that’s already up more than 100 percent.
NEW YORK, April 28 - Orphan drug developer Biohaven Pharmaceuticals' proposed US$133m IPO represents the largest attempt at a biotech new listing this year. Morgan Stanley, Piper Jaffray and Barclays are ...
** Shares of Swiss biotech AC Immune down 6.7 pct to $10.79 in light premarket trading on block sale ** Sources say Jefferies re-offered 1.9 mln shares at $11, roughly 5-pct discount to stock's $11.57 ...
PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Atul Pande, M.D., as the Company’s Chief Medical Officer. In this new role, Dr. Pande will oversee all clinical operations across PureTech Health’s pipeline and work closely with the team to de-risk and advance opportunities that hold the most potential for patients. Dr. Pande commented: “I am proud and delighted to join this stellar team and hope to be instrumental in enabling the launch of some of the truly innovative medicines in the PureTech Health pipeline.